New Hope for Most Severe Chronic Cases of Lyme Disease! Part One

New Hope for Most Severe Chronic Cases of Lyme Disease! Part One

Has anyone heard of Lumbrokinase?  Well, if you haven’t, lumbrokinase is a group of six, novel proteolytic enzymes derived from the earthworm Lumbricus Rubellus, and it is slowly establishing itself as possibly the best and brightest new treatment for chronic Lyme sufferer.

I say “new treatment” because it is new information for me – generously supplied by a fellow “Lymie” Ted Patterson who has tried it and “feels better than he has in years”.  The more I researched this enzyme, the more excited I have become.

First, lumbrokinase has been used successfully in China’s four top hospitals in nerve and infectious diseases since 1995 without any harmful side effects.  Initially used for the potent ability to dissolve blood clots and vein thrombosis, it was soon discovered to improve the quality of blood in a number of ways that are still being discovered.

According to Allery Research Group,  medical reports from leading researchers and doctors have further discovered the power of lumbrokinase to not only dissolve clots which obviously helps protect against heart disease and strokes, but also:

to lower fibrinogen levelsin cancer patients, which is strongly associated in scientific studies with better outcomes,

  • strongly associated in scientific studies with better outcomes, less metastasis, and slower growth of tumors;
  • to offer antiplatelet, anti-thrombotic and self-destructive cellular activity, remarkably regulating hypercoagulation; and most importantly for us,
  • to dissolve bacterial biofilms present in chronic infections in conditions like autism and Lyme disease, allowing antimicrobials and anti-bacterials as well as our own immune system to work effectively and quickly to destroy the colonies that hide behind the biofilms.

Biofilms have been recently discovered as one of the key biological roadblocks to curing many chronic diseases, especially (for our purposes) Lyme disease. It is a remarkable breakthrough, and it ultimately could have a huge effect on Lyme disease sufferers and possibly their life insurance quotes and policies because of a longer life expectancy among those infected.

Peta Cohen, M.S., R.D.,  is the founder of Total Life Center in Northern New Jersey, and has a Masters Degree in Clinical Nutrition, was recently interviewed by Allergy Research Group (read entire interview here), and offers these insights into biofilms:

“I do a tremendous amount of testing and assessing the children through urine and fecal analysis. What got me so interested in nattokinase and lumbrokinase was the concept of what a biofilm infection actually is. If you do a medline search on biofilms and platelet aggregation, fibrinogen, and fibrin, boom, it’s there right in your face.

“Bacteria build biofilms by first aggregating together, and then rapidly weaving this protective web or matrix around them.  They build a polymeric matrix. It’s a sticky, gluey, mucus-y goop and it’s got fibrin in it to give it an intact structure. The bacteria recruit fibrinogen to create fibrin as part of that matrix. At that point they can shed their outer membrane, which has the proteins that serve as antigens and as a target of the missile of the immune system. They’re very protected. They’re very crafty in creating a way to survive and procreate and hide from the immune system.”

In neurological Lyme disease, the biofilm is believed to be constructed of actual bits and pieces of our myelin sheath which covers and protects our actual nerves that make up our central nervous system.  So when the immune system calls for killer cells to destroy the invaders, our immune system can actually attack our central nervous system trying to break through the biofilm and destroy the infection which they cannot do.

So, as lumbrokinase dissolves this biofilm, we have hope that our killer cells, or in more critical cases where the immune system is no longer working effectively, antibiotics (pharmaceutical or herbal) will be able to destroy the infection and return us to health!

See product here.

Look for Part Two on “nattokinase”, and please comment if you have any experience to relate regarding lumbrokinase.

To read excerpts from LLD’s who are using lumbrokinase successfully, read:

Two Doctors Use Lumbrokinase to Help Conquer Lyme Disease

(Originally posted on September 28, 2011, updated August 2013)

(Visited 83 times, 1 visits today)
Subscribe to Jenna's Lyme Blog
Yes, I want to subscribe. I understand I will only receive one email each month when there are new posts.
This entry was posted in Alternative Treatment Protocols, Biofilm, Chronic Lyme Disease, Lyme Disease Treatment, Research and Development and tagged , , , , , , , . Bookmark the permalink.

3 Responses to New Hope for Most Severe Chronic Cases of Lyme Disease! Part One

  1. Pingback: Happy Ending After Years of Suffering With Chronic Lyme Disease and Morgellons » Jenna's Lyme Blog

  2. Grace Kramer says:

    I have been using Lumbrokinase for about four months with Cat’s Claw, Banderol and Andographis plus a meriad of other supplements (S. Buhner’s protocol) I had lyme from age 7 until 47 and treated with antibiotics for two years and Cats Claw for one at the end. I had good recovey because I saw a LLMD with a naturopathic view of medicine who used a well rounded nutritional approach along with antibiotics. I contracted Lyme again last year when I moved to Maine. I was very, very sick. I found a LLDO in Kennebunk who is supporting me in the Herbal protocol this time. I had a hard time with Herxing in the beginning. I have good and bad periods still. I feel the Lumbrokinase makes a difference. I am showing allergies to Japanese knotweed which is slowing me down a bit. When you’re on so many supplements and herbs its difficult to know exactly which one is doing what. I am however impressed that the Herbal protocol is licking the disease with no help from antibiotics. Hallelujah!! Great article. Keep ’em coming. Grace

Leave a Reply

Your email address will not be published. Required fields are marked *